Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4168658 | 0.84 | TSHR (0.47) | TAAR1TSHRLMNAADRA1DTDP1 | |
| SCHEMBL2030841 | 0.74 | TAAR1 (0.71) | TAAR1TSHRPTGS1PTGS2ADRA2A | |
| SCHEMBL4671779 | 0.74 | — | — | |
| SCHEMBL9472736 | 0.72 | CYP2C19 (0.40) | TAAR1TSHRADRA2AADRA2BADRA2C | |
| SCHEMBL4715479 | 0.71 | DAO (0.47) | TAAR1LMNATDP1SMN1; SMN2NPC1 | |
| SCHEMBL11736566 | 0.70 | FBP1 (0.38) | LMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL5757569 | 0.70 | HPGD (0.37) | TAAR1TSHRADRA1DTDP1SMN1; SMN2 | |
| SCHEMBL4775873 | 0.69 | TAAR1 (0.44) | TAAR1TSHRLMNAADRA1D | |
| SCHEMBL11185497 | 0.69 | FDPS (0.33) | — | |
| SCHEMBL1449511 | 0.68 | ALDH1A1 (0.50) | TSHRLMNASMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2922832-B1 | GLUTAMINASE INHIBITORS AND METHODS OF USE | AGIOS PHARMACEUTICALS INC (US) | 2019-10-09 | — | — | EP | disclosed |
| US-10414740-B2 | Glutaminase inhibitors and method of use | AGIOS PHARMACEUTICALS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| US-20180370930-A1 | GLUTAMINASE INHIBITORS AND METHOD OF USE | SERVIER PHARMACEUTICALS LLC | 2018-12-27 | — | — | US | disclosed |
| US-10011574-B2 | Glutaminase inhibitors and method of use | AGIOS PHARMACEUTICALS, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-9303002-B2 | Compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20150299152-A1 | GLUTAMASE INHIBITORS AND METHOD OF USE | SERVIER PHARMACEUTICALS LLC | 2015-10-22 | — | — | US | disclosed |
| EP-2922832-A1 | GLUTAMASE INHIBITORS AND METHOD OF USE | Agios Pharmaceuticals, Inc. (US) | 2015-09-30 | — | — | EP | disclosed |
| WO-2014081925-A1 | GLUTAMASE INHIBITORS AND METHOD OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2014-05-30 | — | — | WO | disclosed |
| US-20140142146-A1 | COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2014-05-22 | — | — | US | disclosed |
| US-7741354-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2010-06-22 | — | — | US | disclosed |
| US-20080207715-A1 | Novel Inhibitors of Glutaminyl Cyclase | PROBIODRUG AG (DE) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011574-B2 | Glutaminase inhibitors and method of use | GLS, GLS2, GLUL | TAAR1 4666/4885TSHR 4186/4885PTGS1 2322/4885 |
| US-10414740-B2 | Glutaminase inhibitors and method of use | GLS, GLS2, GLUL | TAAR1 4666/4885TSHR 4186/4885PTGS1 2322/4885 |
| US-20150299152-A1 | GLUTAMASE INHIBITORS AND METHOD OF USE | GLS, GLS2, GLUL | TAAR1 4692/4885TSHR 4337/4885PTGS1 1989/4885 |
| US-20180370930-A1 | GLUTAMINASE INHIBITORS AND METHOD OF USE | GLS, GLS2, GLUL | TAAR1 4666/4885TSHR 4186/4885PTGS1 2322/4885 |
| US-20140142146-A1 | COMPOUNDS AND THEIR METHODS OF USE | GLS, GLS2, GLUL | TAAR1 4789/4885TSHR 4360/4885PTGS1 2631/4885 |
| US-20080207715-A1 | Novel Inhibitors of Glutaminyl Cyclase | GLS, GLS2, GLUL | TAAR1 1227/4885TSHR 384/4885PTGS1 1371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.